Exelixis plans $165 million funding to develop anticancer rejected by GSK and BMS
11 March 2011
Nancy Faigen
Please Login to read the full article.
11 March 2011
Nancy Faigen
Nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA's Woodcock attributes 35 NME approvals to agency flexibility, creativity
- Clovis' $75M offering follows IPO, as pancreatic cancer candidate could carve out a niche
- Merrimack still ambitious for IPO as others wait in the wings
- Exelixis gains $12m upfront in Merck PI3K-delta deal
ANALYSIS
Other Informa Analysis
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
